In addition, there were only some placebo-controlled randomized controlled trials (RCTs) to investigate the efficacy of recombinant human erythropoietin in anemia profiles; none of these RCTs provided extra information about the multiple comparisons between different active treatments [7,16,17,18]. The gene discussed is EPO; the disease is anemia.